Ocugen Inc. (OCGN)
NASDAQ: OCGN
· Real-Time Price · USD
0.74
-0.01 (-0.96%)
At close: May 01, 2025, 3:59 PM
0.74
0.31%
After-hours: May 01, 2025, 06:04 PM EDT
-0.96% (1D)
| Bid | 0.72 |
| Market Cap | 215.43M |
| Revenue (ttm) | 4.05M |
| Net Income (ttm) | -54.05M |
| EPS (ttm) | -0.2 |
| PE Ratio (ttm) | -3.69 |
| Forward PE | -3 |
| Analyst | Buy |
| Ask | 0.76 |
| Volume | 2,505,302 |
| Avg. Volume (20D) | 3,793,390 |
| Open | 0.74 |
| Previous Close | 0.75 |
| Day's Range | 0.73 - 0.77 |
| 52-Week Range | 0.52 - 2.06 |
| Beta | 3.79 |
About OCGN
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related ...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 3, 2014
Employees 95
Stock Exchange NASDAQ
Ticker Symbol OCGN
Website https://www.ocugen.com
Analyst Forecast
According to 3 analyst ratings, the average rating for OCGN stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 848.90% from the latest price.
Stock Forecasts9 months ago
-7.8%
Ocugen shares are trading lower after the company ...
Unlock content with
Pro Subscription
9 months ago
-4.08%
Ocugen shares are trading lower after the company announced an underwritten public offering.
